<pzf class="zknxpu"></pzf>

南宫NG28基因

Be the most trusted biotech company

2022-04-11

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA
2022-04-08

First Patient Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for treatment of Ophthalmic Diseases in the EU
2022-04-07

HANSIZHUANG Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer
2022-03-31

Henlius Anti-PD-1 mAb Serplulimab IND for MRCT Phase 3 Studies on First-Line LS-SCLC Patients Approved by NMPA
2022-03-25

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG
2022-03-21

Henlius Published Phase 2 Study Results of Novel anti-PD-1 mAb Serplulimab for the treatment of advanced cervical cancer patients at SGO 2022
2022-03-18

Henlius’ Potential First-in-Class Anti-PD-L1×TIGIT Bispecific Antibody HLX301 IND Approved by NMPA
2022-03-17

Evolving from Biotech to Biopharma, Mapping out the Future
2022-03-16

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

1
...
3
4
5
6
7